NTRA — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-07

• Our ability to increase our revenues will depend on our ability to further penetrate our core markets in oncology, organ health, and women’s health and, in particular, generate sales through our direct sales force, develop and commercialize additional tests, obtain reimbursement from additional thir…

• Amortization of acquired intangible assets5,707 — 5,707 100.0

• Total revenues are comprised of product revenues, which are primarily driven by sales of our Panorama and Horizon tests, Signatera and other oncology testing, and licensing and other revenues, which primarily includes development licensing revenue and licensing of our Constellation software. Total r…

• We derive our revenues from tests based on units reported to customers—tests delivered with a result. All reported units are either accessioned in our laboratories or processed outside of our laboratories. As noted in the section titled “Overview” above, the number of tests that we process is a key …

• During the three months ended June 30, 2026, product revenues increased by $203.5 million, or 37.4%, compared to the three months ended June 30, 2025, as a result of the continued revenue growth from increased test volumes, and average selling price improvements. During the three months ended June 3…

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• Our ability to increase our revenues will depend on our ability to further penetrate the domestic and international markets and, in particular, generate sales through our direct sales force, develop and commercialize additional tests, obtain reimbursement from additional third-party payers and incre…

• Entering into in-network contracts continues to be an important part of our business strategy, as we believe that in-network coverage of our tests by third-party payers is crucial to our growth and long-term success, as in-network pricing is more predictable than out-of-network pricing, enables us t…

• our revenues and gross margins. We intend to mitigate any impact by driving more business from our most profitable accounts.

• Comparison of the three months ended March 31, 2026 and 2025

• Amortization of acquired intangible assets5,709 — 5,709 100.0

Text added vs the prior filing · source: 10-Q · 2026-08-07

• On June 12, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1 …

• Second Amendment to Supply Agreement, dated September 21, 2015, by and between Registrant and Illumina, Inc.

• Third Amendment to Supply Agreement, dated June 8, 2016, by and between Registrant and Illumina, Inc.

• Fourth Amendment to Supply Agreement, dated January 3, 2019, by and between Registrant and Illumina, Inc.

• †The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Natera, Inc. under the

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• On March 5, 2026, Steve Chapman, our chief executive officer, modified a Rule 10b5-1 Trading Plan to provide for the potential sale of 180,643 shares of our common stock pursuant to the terms of the plan between June 4, 2026 and March 31, 2028. A significant portion of the shares subject to the plan…

• On March 13, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1…

• †The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Natera, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,…

Text added vs the prior filing · source: 10-Q · 2026-08-07

• On June 12, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1 …

• Second Amendment to Supply Agreement, dated September 21, 2015, by and between Registrant and Illumina, Inc.

• Third Amendment to Supply Agreement, dated June 8, 2016, by and between Registrant and Illumina, Inc.

• Fourth Amendment to Supply Agreement, dated January 3, 2019, by and between Registrant and Illumina, Inc.

• †The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Natera, Inc. under the

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• On March 5, 2026, Steve Chapman, our chief executive officer, modified a Rule 10b5-1 Trading Plan to provide for the potential sale of 180,643 shares of our common stock pursuant to the terms of the plan between June 4, 2026 and March 31, 2028. A significant portion of the shares subject to the plan…

• On March 13, 2026, Matthew Rabinowitz, our executive chairman, adopted a trading arrangement for the sale of shares of our common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Rabinowitz’ Rule 10b5-1…

• †The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of Natera, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,…